Results 141 to 150 of about 1,115 (163)

Avatrombopag/hydroxycarbamide

Reactions Weekly, 2023
openaire   +1 more source

Avatrombopag/eltrombopag

Reactions Weekly, 2023
openaire   +1 more source

Phase 2 Study of Avatrombopag in Japanese Patients With Chronic Liver Disease and Thrombocytopenia

Hepatology Research, 2022
Elena Santagostino, Hirokazu Takahashi, Yuichiro Eguchi   +2 more
exaly  

An Evaluation of Avatrombopag for the Treatment of Thrombocytopenia

Expert Opinion on Pharmacotherapy, 2021
Hanny Al-Samkari, David John Kuter
exaly  

Avatrombopag/eltrombopag/romiplostim

Reactions Weekly, 2022
openaire   +1 more source

Antithymocyte-globulin/Avatrombopag/Ciclosporin

Reactions Weekly, 2023
openaire   +1 more source

Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors

Journal of Clinical Pharmacology, 2018
Maiko Nomoto, Ziad Hussein, Jim Ferry
exaly  

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects

Clinical Pharmacology in Drug Development, 2018
Maiko Nomoto, Jagadeesh Aluri, Jim Ferry
exaly  

Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double-Blind, Dose-Rising, Placebo-Controlled Phase 1 Studies

British Journal of Haematology, 2018
David John Kuter, David J Kuter
exaly  

Summary of opinion: Doptelet,avatrombopag

Case Medical Research, 2019
openaire   +2 more sources